Search Results

physIQ today announced a strategic collaboration with InCarda Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases.

InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-in-class inhaled therapies for cardiovascular diseases, today announced that it has successfully completed an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for InRhythm™ (flecainide for inhalation) for the treatment of atrial fibrillation.

InCarda Therapeutics, Inc. (“InCarda”), today provided a broad corporate update highlighting significant progress for the company’s last-stage development program for InRhythm™ (flecainide for inhalation) in patients with atrial fibrillation, as well as the expansion of its senior management team.

InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today announced dosing of the first U.S. patient in the company’s multinational INSTANT Phase 2 clinical trial of InRhythm™ (flecainide for inhalation) in patients with recent-onset paroxysmal atrial fibrillation (PAF).

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.